Dynamic Advisor Solutions LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 5.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 89,868 shares of the biopharmaceutical company’s stock after acquiring an additional 4,799 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Pfizer were worth $4,652,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. State Street Corp increased its position in Pfizer by 1.8% during the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company’s stock worth $16,818,434,000 after buying an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC increased its position in Pfizer by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company’s stock worth $5,952,333,000 after buying an additional 1,471,980 shares during the last quarter. Norges Bank acquired a new position in Pfizer during the fourth quarter worth approximately $3,351,891,000. Nuveen Asset Management LLC increased its position in Pfizer by 18.0% during the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock worth $1,658,518,000 after buying an additional 4,278,167 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in Pfizer by 2.0% during the third quarter. UBS Asset Management Americas Inc. Now owns 23,728,801 shares of the biopharmaceutical company’s stock worth $1,020,576,000 after buying an additional 457,513 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company’s stock.
In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The stock was sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at $585,250.16. The disclosure for this sale can be found here. Insiders have sold 41,126 shares of company stock valued at $2,075,003 over the last 90 days. Corporate insiders own 0.05% of the company’s stock.
A number of equities analysts have weighed in on the company. The Goldman Sachs Group set a $51.00 price target on Pfizer in a research report on Wednesday, May 25th. Berenberg Bank set a $50.00 target price on Pfizer in a research report on Friday, May 27th. Wells Fargo & Company decreased their target price on Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. SVB Leerink began coverage on Pfizer in a research report on Monday, May 23rd. They issued a “market perform” rating and a $55.00 target price on the stock. Finally, Citigroup upped their target price on Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a research report on Tuesday, April 5th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $57.26.
Shares of PFE stock opened at $49.07 on Thursday. The stock has a 50 day simple moving average of $50.57 and a 200 day simple moving average of $52.22. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a 1 year low of $38.82 and a 1 year high of $61.71. The stock has a market cap of $275.33 billion, a P/E ratio of 11.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.76.
Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business had revenue of $25.66 billion for the quarter, compared to the consensus estimate of $24.73 billion. During the same quarter in the previous year, the company earned $0.93 earnings per share. The firm’s revenue for the quarter was up 76.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 6.61 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.26%. The ex-dividend date was Thursday, May 12th. Pfizer’s payout ratio is presently 36.70%.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.